Identification and characterization of linezolid-resistant cfr-positive Staphylococcus aureus USA300 isolates from a New York City medical center.

Autor:	Locke JB; Trius Therapeutics, Inc., San Diego, California, USA jlocke@cidara.com., Zuill DE; Trius Therapeutics, Inc., San Diego, California, USA., Scharn CR; Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska, USA., Deane J; Eurofins Global Central Laboratory, Chantilly, Virginia, USA., Sahm DF; Eurofins Global Central Laboratory, Chantilly, Virginia, USA., Goering RV; Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska, USA., Jenkins SG; New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, USA., Shaw KJ; Trius Therapeutics, Inc., San Diego, California, USA.
Jazyk:	angličtina
Zdroj:	Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2014 Nov; Vol. 58 (11), pp. 6949-52. Date of Electronic Publication: 2014 Aug 18.
DOI:	10.1128/AAC.03380-14
Abstrakt:	The cfr gene was identified in three linezolid-resistant USA300 methicillin-resistant Staphylococcus aureus (MRSA) isolates collected over a 3-day period at a New York City medical center in 2011 as part of a routine surveillance program. Each isolate possessed a plasmid containing a pSCFS3-like cfr gene environment. Transformation of the cfr-bearing plasmids into the S. aureus ATCC 29213 background recapitulated the expected Cfr antibiogram, including resistance to linezolid, tiamulin, clindamycin, and florfenicol and susceptibility to tedizolid. (Copyright © 2014, American Society for Microbiology. All Rights Reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu